FDA approved Novartis’ Mayzent siponimod to treat adults with relapsing forms of multiple sclerosis, including secondary progressive MS with active disease, relapse-remitting MS and clinically isolated syndrome. Novartis AG (NYSE:NVS; SIX:NOVN) said it plans to launch the second-generation S1PR1 agonist in the U.S. in about one week.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,